Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

NCT04134260 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04134260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 16, 2020
Completion date
November 1, 2031
Enrollment
586 (estimated)
Sites
350

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iva prostate cancer ajcc v8